AdvaMed’s National Testing Registry: Shipments of COVID-19 Molecular Diagnostic Tests Reach 100 Million
The Advanced Medical Technology Association (AdvaMed) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest data from the association’s national testing registry.
“The 100-million mark represents yet another extraordinary milestone as the medical technology industry ramps up to meet the demand for testing posed by the coronavirus pandemic,” said AdvaMed president and CEO Scott Whitaker. “The diagnostics industry will continue to work 24/7, around the clock, to ensure widespread availability of test kits and supplies, doing everything possible to help beat this public health crisis.”
Unveiled July 21, AdvaMed’s Registry compiles information from diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. The registry will provide weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.